Tafenoquine
Caitlin Soto , PharmD, BCIDP, Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Two different brand names were FDA-approved in 2018:
- Krintafel™ — radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving chloroquine therapy for acute P. vivax infection.
- Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
- Concomitant use with antimalarials other than chloroquine is not recommended because of the risk of P. vivax recurrence.
- Arakoda™ — prophylaxis of malaria in patients ≥18 years of age.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- P. ovale radical cure:
- Off-label radical cure in patients ≥16 years with normal quantitative G6PD activity when chloroquine/hydroxychloroquine is used for acute therapy.
- Babesia microti babesiosis:
- Investigational salvage therapy for persistent or relapsing infection, particularly in highly immunocompromised patients with failure or resistance to standard regimens.
- Clinical experience is limited to case reports/small case series.
- Tafenoquine is not FDA-approved for babesiosis, and no standardized dose or duration has been established.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.